QIAGEN Announces Appointment of New Supervisory Board Member

Rhea-AI Summary

QIAGEN has appointed Dr. Toralf Haag to its Supervisory Board effective immediately, expanding its membership to seven. Haag, who also joins the Audit Committee, brings extensive experience from his roles in leading companies like Voith and Lonza Group. This strategic move aims to enhance the Board's expertise in Life Sciences and diagnostics. The appointment is part of a broader review process initiated in 2020 aimed at strengthening corporate governance and maximizing stakeholder value.

Positive

• Dr. Haag's diverse experience in corporate leadership may provide fresh perspectives.
• The expansion of the Supervisory Board supports enhanced governance and strategic oversight.

Negative

• Concerns may arise regarding continuity and potential experience gaps during the transition.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. He will also become a member of the Audit Committee.

Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Dr. Haag brings the number of current Supervisory Board members to seven.

“We are pleased to welcome Dr. Toralf Haag to our Supervisory Board. This appointment further deepens our expertise and experience in the Life Sciences and diagnostics,” said Lawrence Rosen, Chairman of the Supervisory Board. “This appointment of Dr. Haag is also one of the actions to come out of a review process we initiated during 2020. The Supervisory Board reaffirms its commitment to the highest level of excellence in corporate governance and working effectively with the management team to create value for QIAGEN’s stakeholders, including its shareholders.”

Dr. Haag has served since October 2018 as Chairman of the Corporate Board of Management of Voith GmbH & Co. KGaA in Germany, a global technology company with more than EUR 4 billion in annual sales and over 19,000 employees. Before joining Voith in October 2016 as Chief Financial Officer, he served for more than 11 years as CFO and Member of the Executive Committee of Lonza Group AG since August 2005. Dr. Haag began his career in 1994 as the personal assistant to the CEO of Thyssen Handelsunion AG after earning a degree in Business Administration from the University of Augsburg and a Ph.D. at the University of Kiel.

Please find the full press release here

View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005248/en/

FAQ

Who is Dr. Toralf Haag and what experience does he bring to QIAGEN?

Dr. Toralf Haag is the newly appointed member of QIAGEN's Supervisory Board, previously serving as Chairman at Voith and CFO at Lonza Group, bringing extensive leadership experience in the Life Sciences sector.

What is the significance of Dr. Haag's appointment to the Supervisory Board?

Dr. Haag's appointment is part of a strategy to enhance the Board's expertise in Life Sciences and diagnostics, aiming to improve corporate governance and create shareholder value.

How many members are currently on QIAGEN's Supervisory Board?

With Dr. Haag's appointment, QIAGEN's Supervisory Board now consists of seven members.

When was Dr. Haag appointed to the Supervisory Board of QIAGEN?

Dr. Toralf Haag was appointed to the Supervisory Board of QIAGEN immediately upon the announcement.